Compare LZM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | VNDA |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | Isle of Man | United States |
| Employees | 93 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.3M | 361.4M |
| IPO Year | N/A | 2005 |
| Metric | LZM | VNDA |
|---|---|---|
| Price | $3.75 | $6.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $14.90 |
| AVG Volume (30 Days) | 741.0K | ★ 887.6K |
| Earning Date | 03-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $86.37 | $21.35 |
| Revenue Next Year | $202.49 | $37.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $3.07 | $4.14 |
| 52 Week High | $6.40 | $9.91 |
| Indicator | LZM | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 49.21 |
| Support Level | $3.62 | $5.97 |
| Resistance Level | $4.32 | $6.73 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 22.32 | 81.36 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.